Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging

[1] Wolmark N(2001)Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Inst Monogr 30 96-102

[2] Wang J(2001)Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224-4237

[3] Mamounas E(2007)Measurements of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 4414-4422

[4] Bryant J(2008)Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27 J Clin Oncol 26 778-785

[5] Fisher B(2004)Locally advanced breast cancer comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy Eur Radiol 14 1371-1379

[6] van der Hage JA(2005)Prospective comparison of mammography, sonography and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer AJR Am J Roentgenol 184 868-877

[7] van de Velde CJ(2002)Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy AJR Am J Roentgenol 179 1193-1199

[8] Julien JP(2006)MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy Clin Radiol 61 946-953

[9] Tubiana-Hulin M(2009)Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am J Surg 198 500-504

[10] Vandervelden C(2009)New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247

[1] Wolmark N(2001)Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Inst Monogr 30 96-102

[2] Wang J(2001)Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224-4237

[3] Mamounas E(2007)Measurements of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 4414-4422

[4] Bryant J(2008)Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27 J Clin Oncol 26 778-785

[5] Fisher B(2004)Locally advanced breast cancer comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy Eur Radiol 14 1371-1379

[6] van der Hage JA(2005)Prospective comparison of mammography, sonography and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer AJR Am J Roentgenol 184 868-877

[7] van de Velde CJ(2002)Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy AJR Am J Roentgenol 179 1193-1199

[8] Julien JP(2006)MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy Clin Radiol 61 946-953

[9] Tubiana-Hulin M(2009)Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am J Surg 198 500-504

[10] Vandervelden C(2009)New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247